Literature DB >> 30721141

Procalcitonin (PCT)-guided antibiotic stewardship: an international experts consensus on optimized clinical use.

Philipp Schuetz1,2, Albertus Beishuizen3, Michael Broyles4, Ricard Ferrer5, Gaetan Gavazzi6, Eric Howard Gluck7, Juan González Del Castillo8, Jens-Ulrik Jensen9,10, Peter Laszlo Kanizsai11, Andrea Lay Hoon Kwa12, Stefan Krueger13,14, Charles-Edouard Luyt15, Michael Oppert16, Mario Plebani17, Sergey A Shlyapnikov18,19, Giulio Toccafondi20, Jennifer Townsend21, Tobias Welte22, Kordo Saeed23,24.   

Abstract

Background Procalcitonin (PCT)-guided antibiotic stewardship (ABS) has been shown to reduce antibiotics (ABxs), with lower side-effects and an improvement in clinical outcomes. The aim of this experts workshop was to derive a PCT algorithm ABS for easier implementation into clinical routine across different clinical settings. Methods Clinical evidence and practical experience with PCT-guided ABS was analyzed and discussed, with a focus on optimal PCT use in the clinical context and increased adherence to PCT protocols. Using a Delphi process, the experts group reached consensus on different PCT algorithms based on clinical severity of the patient and probability of bacterial infection. Results The group agreed that there is strong evidence that PCT-guided ABS supports individual decisions on initiation and duration of ABx treatment in patients with acute respiratory infections and sepsis from any source, thereby reducing overall ABx exposure and associated side effects, and improving clinical outcomes. To simplify practical application, the expert group refined the established PCT algorithms by incorporating severity of illness and probability of bacterial infection and reducing the fixed cut-offs to only one for mild to moderate and one for severe disease (0.25 μg/L and 0.5 μg/L, respectively). Further, guidance on interpretation of PCT results to initiate, withhold or discontinue ABx treatment was included. Conclusions A combination of clinical patient assessment with PCT levels in well-defined ABS algorithms, in context with continuous education and regular feedback to all ABS stakeholders, has the potential to improve the diagnostic and therapeutic management of patients suspected of bacterial infection, thereby improving ABS effectiveness.

Entities:  

Keywords:  ABx stewardship; bacterial infection; biomarker; procalcitonin; respiratory tract infections; sepsis

Mesh:

Substances:

Year:  2019        PMID: 30721141     DOI: 10.1515/cclm-2018-1181

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  41 in total

1.  Clinical outcomes and costs associated with procalcitonin utilization in hospitalized patients with pneumonia, heart failure, viral respiratory infection, or chronic obstructive pulmonary disease.

Authors:  Stacy Aric Johnson; Austin Bernard Rupp; Kirsten Leigh Rupp; Santosh Reddy
Journal:  Intern Emerg Med       Date:  2021-01-16       Impact factor: 3.397

Review 2.  Utility of Procalcitonin as a Biomarker for Sepsis in Children.

Authors:  Kevin J Downes; Julie C Fitzgerald; Scott L Weiss
Journal:  J Clin Microbiol       Date:  2020-06-24       Impact factor: 5.948

3.  Development of an antibody-free ID-LC MS method for the quantification of procalcitonin in human serum at sub-microgram per liter level using a peptide-based calibration.

Authors:  Huu-Hien Huynh; Amandine Bœuf; Maxence Derbez-Morin; Anne-Marie Dupuy; Béatrice Lalere; Vincent Delatour; Joëlle Vinh
Journal:  Anal Bioanal Chem       Date:  2021-05-14       Impact factor: 4.142

Review 4.  Role of procalcitonin use in the management of sepsis.

Authors:  Claudia Gregoriano; Eva Heilmann; Alexandra Molitor; Philipp Schuetz
Journal:  J Thorac Dis       Date:  2020-02       Impact factor: 2.895

5.  Procalcitonin in Pediatric Sepsis: What Is It Good for?

Authors:  Kevin J Downes
Journal:  J Pediatric Infect Dis Soc       Date:  2021-12-31       Impact factor: 5.235

6.  Associations between urinary 3-indoxyl sulfate, a gut microbiome-derived biomarker, and patient outcomes after intensive care unit admission.

Authors:  Selena Z Kuo; Katja Dettmer; Medini K Annavajhala; David H Chong; Anne-Catrin Uhlemann; Julian A Abrams; Peter J Oefner; Daniel E Freedberg
Journal:  J Crit Care       Date:  2021-01-21       Impact factor: 4.298

Review 7.  Rapid and Point-of-Care Testing in Respiratory Tract Infections: An Antibiotic Guardian?

Authors:  Zaneeta Dhesi; Virve I Enne; Justin O'Grady; Vanya Gant; David M Livermore
Journal:  ACS Pharmacol Transl Sci       Date:  2020-05-12

Review 8.  [Procalcitonin in the intensive care unit : Differential diagnostic and differential therapeutic possibilities].

Authors:  S Großmann; S Schroll; M Pfeifer
Journal:  Med Klin Intensivmed Notfmed       Date:  2020-06-29       Impact factor: 0.840

9.  Procalcitonin as an antibiotic stewardship tool in COVID-19 patients in the intensive care unit.

Authors:  Lesley Heesom; Lucas Rehnberg; Myra Nasim-Mohi; Alexander I R Jackson; Michael Celinski; Ahilanadan Dushianthan; Paul Cook; William Rivinberg; Kordo Saeed
Journal:  J Glob Antimicrob Resist       Date:  2020-07-25       Impact factor: 4.035

10.  The value of serum procalcitonin in the anti-infection therapy of acute stroke patients.

Authors:  Hui-Ling Wang; Ying-Lei Li; Xiao-Fang Li; Zhi-Zun Wang
Journal:  Pak J Med Sci       Date:  2021 Jul-Aug       Impact factor: 1.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.